Dilsher Dhoot, MD, provides an overview of biosimilars in retinal diseases and discusses how he identifies patients suitable for biosimilar therapy.
Harnessing the Potential of Biosimilars in Retinal Disease Management
Dilsher Dhoot, MD, presents two cases involving DME and CRVO, that show remarkable anatomical improvement with a biosimilar comparable to those achieved with reference biologics.
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
NCX 470 gains positive regulatory feedback in China ahead of US NDA submission
2
DSLT for glaucoma and ocular hypertension: Real-world outcomes in 218 eyes
3
FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA)
4
Tinlarebant NDA submission completed for Stargardt disease type 1, targeting first approved therapy
5